Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098920 | 0.94 | CD274 (0.56) | MAOBCD274PDCD1HDAC6SCN3A | |
| SCHEMBL5104982 | 0.88 | CD274 (0.62) | CD274PDCD1PARP15PARP10MTNR1B | |
| SCHEMBL5105122 | 0.82 | SCN8A (0.49) | MAOBCD274PDCD1SCN8ASCN3A | |
| SCHEMBL5096316 | 0.81 | CD274 (0.70) | CD274PDCD1PARP15PARP10 | |
| SCHEMBL5098860 | 0.80 | CD274 (0.58) | CD274PDCD1SCN3AMTNR1B | |
| SCHEMBL5105396 | 0.78 | CD274 (0.66) | MAOBCD274PDCD1SCN3APTPN1 | |
| SCHEMBL5099042 | 0.78 | CD274 (0.66) | CD274PDCD1SCN3AMTNR1B | |
| SCHEMBL5092319 | 0.78 | CD274 (0.57) | MAOBCD274PDCD1SCN3A | |
| SCHEMBL5096232 | 0.76 | KMT2A (0.57) | CD274MTNR1B | |
| SCHEMBL5098924 | 0.76 | CD274 (0.58) | MAOBCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | claimed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | claimed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | disclosed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | SCN7A, HTR7, TRPC7 | MAOB 1074/4885CD274 4861/4885PDCD1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.